How Does This Genetic Tools Business Operate?
Illumina sells tools and systems used for genetic analysis, centered on sequencing workflows. The company’s offering spans instruments, related consumables, and supporting services that tie into ongoing use over time. It operates as a large, established provider within life sciences tools. With a market value around USD 28.4 billion, it sits squarely in the public-market spotlight.
Are Margins Hiding Weak Capital Returns?
FundamentalsFor 2025, reported in USD, revenue was USD 4.34 billion, slipping by 0.7% versus the prior year, while net income came in at USD 850 million. Profitability remained high on a trailing basis, with a 66.72% gross margin alongside a 19.26% operating margin and a 19.42% net profit margin.
The balance sheet shows USD 1.42 billion of cash against USD 499 million of total debt, with depreciation and amortization of USD 203 million. On trailing figures, ROE is 33.99%, while a separate return-on-capital proxy in the dataset is much lower, creating a wide spread between equity returns and capital returns.
Is The Market Overpaying For Growth?
DCF / MultiplesAt USD 187.81, the stock trades above the discounted cash flow range implied by the valuation output. The headline multiples reinforce that positioning, with 33.09x trailing earnings, 27.79x EV/EBITDA, and 6.42x sales.
Valuation Outruns True Returns
TakeawayThe price reads like a business compounding capital at high rates. The operating picture instead looks like margins doing most of the work. For this to hold, capital returns need to rise, not just accounting returns. If that gap persists, the valuation can unwind quickly. The contrarian view is simple: the stock may be paying for a better engine than exists.